Inventiva S.a. Stock Earnings Reports

Inventiva is now fully focused on advancing lanifibranor as a potential oral therapy for MASH. The pivotal Phase III NATiV3 trial completed enrollment in April 2025 (over 1,000 patients in the main cohort plus ~410 in an exploratory cohort) and the company updated its expected topline readout timing to Q4 2026. NATiV3 is powered (>90%) to evaluate a clinically meaningful composite primary endpoint (fibrosis improvement ≥1 stage AND MASH resolution) and was deliberately designed to reflect a real‑world patient mix (substantial type 2 diabetes and background GLP‑1/SGLT2 use). Inventiva sold odiparcil rights to Biossil (potential milestones up to $90M plus royalties) to focus resources on lanifibranor and has strengthened its leadership (CMO, Head Quality & Regulatory, Chief Commercial Strategy). Financially, as of Dec 31, 2025 Inventiva reported ~EUR 231M in cash, cash equivalents and short‑term deposits (proceeds from 2024 structured financing tranche and a U.S. offering in Nov 2025) and estimates funding beyond the anticipated NATiV3 readout, with a cash runway to mid‑Q1 2027 (or mid‑Q3 2027 assuming full exercise of tranche 3 warrants). The company plans to pursue regulatory pathways that could allow conditional/accelerated pathways if appropriate trials are underway at filing, and intends a lean, targeted build toward commercialization while monitoring safety (including class‑typical PPAR‑related fluid retention/weight effects) and preparing for potential post‑approval outcome trials including work in compensated F4 patients.